WBDE: WP107 oral solution for the treatment of "myasthenia gravis" clinical trial application approved
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, WBDE announced that its wholly-owned subsidiary, WBDE Pharmaceutical Group Co., Ltd., recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The clinical trial application for the company's independently developed WP107 oral solution for the treatment of "myasthenia gravis" has been approved
According to the Zhitong Finance APP, WBDE (002082.SZ) announced that its wholly-owned subsidiary, WBDE Pharmaceutical Group Co., Ltd., recently received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration. The clinical trial application for the company's independently developed WP107 oral solution for the treatment of "myasthenia gravis" has been approved